Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
DIFLUCAN IN SODIUM CHLORIDE 0.9% vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluconazole, a bis-triazole antifungal, selectively inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
400 mg IV on day 1, then 200 mg IV once daily; for esophageal candidiasis: 200 mg IV on day 1, then 100 mg IV once daily
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal elimination half-life is approximately 30 hours (range 20-50 hours) in adults with normal renal function. Prolonged in renal impairment (up to 98 hours in creatinine clearance <20 mL/min).
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Primarily renal excretion of unchanged drug (~80% of dose). Approximately 11% excreted as metabolites. Biliary/fecal excretion accounts for <5%.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte